Clinical Evidence Behind
Products and Intervention Techniques

Comparable clinical outcomes of Ultimaster™ stent with bioresorable polymer coating versus Xience stent with durable polymer coating are maintained up to five years. Particularly remarkable was the low rate of…

5-year clinical outcomes of PCI-treated bifurcation lesions whereby a single stent approach was utilized in 93% of the cases showed similar good safety and efficacy for both Ulimaster™ and Xience stents.…

This study reveals, that throughout the 5-year follow-up period, sirolimus-eluting bioresorbable polymer Ultimaster™ stent (BP-SES), displays similarly good long-term safety and efficacy profile as the…

The trial compares the novel distal radial access with conventional radial access approach, in terms of radial occlusion rates (RAO) at discharge. DISCO RADIAL is the first large international randomized study…

DISCOVERY 1TO3 demonstrated rapid strut coverage of UltimasterTM DES, with the majority of strut coverage process taking place within the first month after stent implantation. The unique sequential OFDI…

37,198 patients enrolled: The biggest real world BP-DES registry in the world. Excellent performance with a TLF rate < 5% in all continents and stent thrombosis rate < 1%.

4,395 patients with Bifurcation lesions treated with Ultimaster™ DES showed acceptable clinical outcomes with TLF 5.1%. Ultimaster™ with POT technique improve clinical outcomes.

1,099 patients with Left main lesions treated with Ultimaster™ DES showed acceptable clinical outcomes.

MASTER DAPT compares abbreviated vs. prolonged DAPT, following implantation with Ultimaster™ or Ultimaster™ Tansei™, in approx. 4,500 "all-comer" patients.

This sub-analysis compares abbreviated vs. prolonged DAPT in high bleeding risk patients presenting with acute or recent myocardial infarction.